Hot Topics in Hypercholesterolemia: Impact of Recent Clinical Trial Data on Clinical Practice

This educational activity is designed for cardiologists and primary care physicians involved in reducing the cardiovascular risks associated with elevated cholesterol levels of their patient populations.

The reporting of several recent trials on the value of lipid-lowering agents to reduce the risk of cardiovascular morbidity and mortality have resulted in extensive media coverage and scientific debate as to the potential implications for patients with elevated cholesterol levels who are at increased risk of such events. Discussing these data in the context of the totality of data on lipid-lowering will be discussed in this continuing education program. This SPOTLIGHT version of Medical Crossfire has as its central goal to provide validation, relevance, and practicality through discussion, debate, and authoritative peer exchange on current controversies as to the role of lipid-lowering agents.

Upon completion of this activity, participants should be able to:

Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor Continuing Medical Education for Physicians.

Temple University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)^™. Physicians should only claim credit commensurate with the extent of their participation in the activity.For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity: somasem@temple.edu. For technical assistance, contact CME@webmd.net.

It is the policy of Temple University School of Medicine, The Albert J. Finestone, M.D. Office for Continuing Medical Education to insure balance, independence, objectivity and scientific rigor in all of it’s sponsored or jointly sponsored educational programs. All faculty participating in programs sponsored or jointly sponsored by Temple University School of Medicine are expected to disclose to the program audience any real or apparent conflict (s) of interest related to the content of their presentation(s).

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, Temple University School of Medicine, Temple University Health System or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

Michael H. Davidson, MD, FACC, FACP
Disclosure: Grant/Research Support: Abbott Laboratories, AstraZeneca Pharmaceuticals, Daiichi-Sankyo, Inc., Merck & Co., Inc., Merck/Schering-Plough, Pfizer Laboratories, Roche Pharmaceuticals, Takeda Pharmaceutical Company; Consultant: Abbott Laboratories, AstraZeneca Pharmaceuticals, Daiichi-Sankyo, Inc., diaDexus, Inc., Merck & Co., Inc., Merck/Schering-Plough, Pfizer Laboratories, Roche Pharmaceuticals, sanofi-aventis U.S. LLC, Synarc, Takeda Pharmaceutical Company; Speakers' Bureau: Abbott Laboratories, AstraZeneca Pharmaceuticals, Daiichi-Sankyo, Inc., diaDexus, Inc., Merck & Co., Inc., Merck/Schering-Plough, Oscient Pharmaceuticals, Pfizer Laboratories, Takeda Pharmaceutical Company; Advisory Board: Abbott Laboratories, Access Health, AstraZeneca Pharmaceuticals, Atherogenics, Daiichi-Sankyo, Inc., Kinemed, Merck & Co., Inc., Merck/Schering-Plough, Oscient Pharmaceuticals, Pfizer Laboratories, PreEmptive Meds, Roche Pharmaceuticals, Takeda Pharmaceutical Company, Xinthria P

Peter H. Jones, MD
Disclosure: Consultant: Abbott Laboratories, AstraZeneca Pharmaceuticals, Pfizer Laboratories; Speakers' Bureau: Abbott Laboratories, AstraZeneca Pharmaceuticals, Merck Schering/Plough, Pfizer Laboratories

Daniel J. Rader, MD
Disclosure: Grant/Research Support: AstraZeneca Pharmaceuticals, Boehringer Ingelheim Corporation, Bristol-Myers Squibb Company, Bruin Pharmaceuticals, GlaxoSmithKline, KOS Pharmaceuticals, Merck & Co. Inc., Pfizer Laboratories, Schering-Plough Corporation, Takeda Pharmaceutical Company; Consultant: Abbott Laboratories, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline, Johnson & Johnson, KOS Pharmaceuticals, Merck & Co. Inc., Merck/Schering-Plough, Pfizer Laboratories, Resverlogix Corp., sanofi-aventis U.S. LLC., Schering-Plough Corporation, Takeda Pharmaceutical Company, Wyeth; Speakers' Bureau: Abbott Laboratories, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Johnson & Johnson, KOS Pharmaceuticals, Merck & Co. Inc., Merck/Schering-Plough, Pfizer Laboratories, sanofi-aventis U.S. LLC, Schering-Plough Corporation, Takeda Pharmaceutical Company, Wyeth